Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Tenet Healthcare Corporation — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.65, while Tenet Healthcare Corporation trades at $200 (market cap $16.57B). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, Tenet Healthcare Corporation nearer its low. Which is the better fit depends on your goals.
| EMB | THC | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $97.74 | $244.80 |
52-Week Low | $91.59 | $148.38 |
Market Cap | — | $16.57B |
Enterprise Value | — | $26.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $95.54, down slightly by 0.03% on the day, with a bearish technical signal driven by moving averages. Recent corporate actions include scheduled dividends for 2026, with payouts of $0.41 and $0.40 per share. News highlights focus on emerging market bond risks and Federal Reserve policy impacts, with the ETF showing a 12% total return over the past year but only 1% year-to-date gains as of May 2026.
The outlook for EMB is cautious due to bearish technical indicators and macroeconomic sensitivities. Key risks include emerging market sovereign default exposure and interest rate volatility. Analyst sentiment is mixed, with attention on Fed policy and global bond market dynamics as critical drivers for future performance.
Tenet Healthcare (THC) trades at $199.10, up 8.39% over the past day, with strong fundamental metrics including a P/E of 10 and net income margin of 7.79%. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $4.82 surpassing the $4.17 estimate. Technical indicators show a bearish trend with support at $187 and resistance at $197, while analyst sentiment remains overwhelmingly positive with 26 buy ratings and a consensus price target of $235.88.
The outlook for THC is favorable due to robust earnings performance and attractive valuation, though near-term price volatility and competitive pressures in healthcare pose risks. Revenue growth is projected to increase from $21.3B in 2025 to $21.9B in 2026, supporting further upside if execution continues. Investors should monitor Q2 2026 earnings due July 24, 2026, for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
